Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

AP News

Galena says Teva will co-develop NeuVax in Israel

NEW YORK (AP) — Galena Biopharma Inc. said Tuesday that Teva Pharmaceutical Industries Ltd., one of the world's largest drugmakers, will develop and market its cancer treatment NeuVax in Israel.

Galena said Teva will handle the development and regulatory process in Israel and conduct at least four clinical trials of NeuVax in the country. The companies did not disclose terms of the deal, but Galena said it will receive "significant royalty payments" on sales of NeuVax if it is approved by Israeli regulators.

NeuVax is intended to induce immunity to breast cancer recurrence in certain patients. The peptide vaccine is intended for women who are not eligible for treatment with Roche's breast cancer drug Herceptin because they have lower levels of the HER-2 gene.

The Lake Oswego, Ore., company does not have any products on the market. NeuVax is its most advanced experimental drug.

Shares of Galena rose 26 cents, or 12.8 percent, to $2.30 in morning trading. Shares of Israel-based Teva picked up 20 cents to $40.75.

blog comments powered by Disqus